Rani Therapeutics
San Jose
About Rani Therapeutics
Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes. They developed the RaniPill capsule, which is Rani's novel, proprietary, and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using the RaniPill capsule. Their development efforts have enabled them to construct an extensive intellectual property portfolio that they believe provides patients with a competitive advantage.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $329.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:RANI
- Website: ranitherapeutics.com
- Phone: (408) 457 3730
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/rani-therapeutics-15388 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.